A rationale to target the SWI/SNF complex for cancer therapy.
about
Open access chemical probes for epigenetic targetsChromatin Remodeling and Transcriptional Control in Innate Immunity: Emergence of Akirin2 as a Novel PlayerGenome-Wide Transcriptional Regulation Mediated by Biochemically Distinct SWI/SNF ComplexesSensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibitionStructure-Based Design of an in Vivo Active Selective BRD9 InhibitorSMARCE1 regulates metastatic potential of breast cancer cells through the HIF1A/PTK2 pathwayThe SWI/SNF ATPases Are Required for Triple Negative Breast Cancer Cell ProliferationThe role of the SWI/SNF chromatin remodeling complex in maintaining the stemness of glioma initiating cellsACTL6A Is Co-Amplified with p63 in Squamous Cell Carcinoma to Drive YAP Activation, Regenerative Proliferation, and Poor Prognosis.New targeted therapies for breast cancer: A focus on tumor microenvironmental signals and chemoresistant breast cancersExpression inactivation of SMARCA4 by microRNAs in lung tumorsAlisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children.Low PBRM1 identifies tumor progression and poor prognosis in breast cancer.Disrupted cooperation between transcription factors across diverse cancer types.Establishing a reliable framework for harnessing the creative power of the scientific crowdThe SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies.Atypical teratoid/rhabdoid tumors-current concepts, advances in biology, and potential future therapies.Genomic and Epigenomic Alterations in CancerTargeting the chromatin remodeling enzyme BRG1 increases the efficacy of chemotherapy drugs in breast cancer cellsATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A.Chromatin remodeling gene ARID2 targets cyclin D1 and cyclin E1 to suppress hepatoma cell progressionLinking long non-coding RNAs and SWI/SNF complexes to chromatin remodeling in cancer.Coffin-Siris syndrome and related disorders involving components of the BAF (mSWI/SNF) complex: historical review and recent advances using next generation sequencing.Progress in the Development of non-BET Bromodomain Chemical Probes.The chromatin-remodeling subunit Baf200 promotes homology-directed DNA repair and regulates distinct chromatin-remodeling complexes.Epigenomic regulation of oncogenesis by chromatin remodeling.Marked for death: targeting epigenetic changes in cancer.Long Non-coding RNAs and their Role in Metastasis.Mammalian SWI/SNF complexes in cancer: emerging therapeutic opportunities.BRD9 Inhibition, Alone or in Combination with Cytostatic Compounds as a Therapeutic Approach in Rhabdoid Tumors.Comprehensive assessment of the expression of the SWI/SNF complex defines two distinct prognostic subtypes of ovarian clear cell carcinoma.The OncoPPi network of cancer-focused protein-protein interactions to inform biological insights and therapeutic strategiesA Subset of Patients with Acute Myeloid Leukemia Has Leukemia Cells Characterized by Chemokine Responsiveness and Altered Expression of Transcriptional as well as Angiogenic RegulatorsEmbryonic transcription factor SOX9 drives breast cancer endocrine resistance.The SWI/SNF subunit Bcl7a contributes to motor coordination and Purkinje cell function.Arid1a Has Context-Dependent Oncogenic and Tumor Suppressor Functions in Liver Cancer.SMARCA2-regulated host cell factors are required for MxA restriction of influenza A viruses.Brg1 inhibits E-cadherin expression in lung epithelial cells and disrupts epithelial integrity.The Mitochondrial DNA-Associated Protein SWIB5 Influences mtDNA Architecture and Homologous Recombination.Molecular alterations of coexisting thyroid papillary carcinoma and anaplastic carcinoma: identification of TERT mutation as an independent risk factor for transformation.
P2860
Q26781872-FC0613F7-5967-48FF-96AA-2A9E372EE5A2Q26796578-7E5C830A-A42E-4C0D-8344-D4B464C59312Q28271584-A9C4935F-AAE2-4A54-BA68-ECF297F76381Q28829718-40D45195-6F70-43CD-88DE-263AAB036F30Q28829832-E3340869-4511-48F6-B3D5-1AA742779458Q28831292-C242A558-B53F-45EF-8961-F7953DA369B8Q30659086-A435B84B-AB19-47BC-A31D-34CD27C0FDDFQ33678542-307C61B3-C7E9-480C-86AB-1C15F9799BC9Q34548405-7567473B-28ED-4189-8828-45B44F09751CQ34706060-3F4B51C4-5293-49F8-A41B-FE950F2B9305Q35063165-053510E7-1952-44CA-A941-EF3CBE68A203Q35789013-D600F97E-84C8-40F4-986B-528EAC00D958Q36095258-FB8CF23C-A0E5-4A97-9CA0-C4464E27021BQ36096560-4550C2CF-CEB4-4B7C-9751-D029D484D864Q36281061-1DD338B0-9917-45B7-80A0-0B7458B42615Q36584337-EA7E9E5A-E0CE-459B-A0BB-999015946463Q36893203-857BF278-44F3-42B4-8F12-EB6523E68A33Q37057145-D47E0B44-7A96-478D-82A7-801904E7A917Q37317194-3DA81961-6A6E-4D13-BA4A-DA15422627CCQ37508792-DF01020C-2E38-49F2-8CEC-FFF2EEB1A99BQ37564581-17330984-0545-49EF-A821-B108E75B51EDQ37650946-46A0E953-CDBF-49CA-AB5F-C2B0FC4F6C35Q38244479-6E6EFA54-D9D6-4D41-B54D-11E021E29C67Q38691377-77C2301D-7E7A-45F0-B92B-56AC8706F263Q38708715-CD827BAC-97C5-4848-AD0D-4F9F922AC506Q38709544-B622CCC0-40AD-469A-AF65-A2178C129597Q38747872-3AF09F29-0638-480B-BA7A-A26F6B126D30Q38818070-B2CA8945-1F9B-483D-94E6-132F9C703872Q39229171-0147C22C-4E30-4A99-BD13-BF22C50AE139Q41183040-EAF45437-6117-45BF-A246-AFB2DF8D5F19Q42317508-64E3A35C-B466-4597-BD95-3159112F4A4CQ42320718-1925D0DC-D5CC-4D15-9743-0FADFB95476CQ42764236-91FE2FDD-BCDC-4922-A27D-FB17CAD8A9B8Q44871921-27E31104-F770-4819-855A-71C99CF58B95Q47102925-04F01CEC-47FB-4D0B-9E28-16270BB71159Q47404707-10BE0F05-DD6B-4022-80B5-F148A1A53D3CQ47546996-4610E070-E617-43A6-A17D-E29BC72ABC0EQ47802348-62FDA3B7-2B0D-429C-AAA4-2086E55BFAB7Q48063436-F89B7FAA-05E3-4A83-9686-2B9B8CEF9514Q48088782-1E3CF121-E4C2-458D-8994-FBAF46CB1B82
P2860
A rationale to target the SWI/SNF complex for cancer therapy.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
A rationale to target the SWI/SNF complex for cancer therapy.
@en
type
label
A rationale to target the SWI/SNF complex for cancer therapy.
@en
prefLabel
A rationale to target the SWI/SNF complex for cancer therapy.
@en
P2860
P1433
P1476
A rationale to target the SWI/SNF complex for cancer therapy.
@en
P2093
Anja F Hohmann
P2860
P304
P356
10.1016/J.TIG.2014.05.001
P577
2014-06-03T00:00:00Z